Covering Every FDA Oncology Approval From October 2025 CURE BPC 157 has a decades long safety record with zero deaths or hospitalizations. Yet, it's unapproved because the FDA process is too expensive and the business model doesn't allow for profit. Approved drugs with Regulatory Alert: FDA's April 2026 Update on BPC 157 and GHK Cu Holt Law FDA's Overreach on Compounded Peptides